Biomaterial Database

[Endoxan in ovarian cancer]. 1974

I Campodónico, and A Soldati, and A Rodríguez

UI	MeSH Term	Description	Entries
D007275	Injections, Intravenous	Injections made into a vein for therapeutic or experimental purposes.	Intravenous Injections,Injection, Intravenous,Intravenous Injection
D008875	Middle Aged	An adult aged 45 - 64 years.	Middle Age
D010051	Ovarian Neoplasms	Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.	Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D002986	Clinical Trials as Topic	Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries.	Clinical Trial as Topic
D003520	Cyclophosphamide	Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.	(+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D004341	Drug Evaluation	Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals.	Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260	Female		Females
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000230	Adenocarcinoma	A malignant epithelial tumor with a glandular organization.	Adenocarcinoma, Basal Cell,Adenocarcinoma, Granular Cell,Adenocarcinoma, Oxyphilic,Adenocarcinoma, Tubular,Adenoma, Malignant,Carcinoma, Cribriform,Carcinoma, Granular Cell,Carcinoma, Tubular,Adenocarcinomas,Adenocarcinomas, Basal Cell,Adenocarcinomas, Granular Cell,Adenocarcinomas, Oxyphilic,Adenocarcinomas, Tubular,Adenomas, Malignant,Basal Cell Adenocarcinoma,Basal Cell Adenocarcinomas,Carcinomas, Cribriform,Carcinomas, Granular Cell,Carcinomas, Tubular,Cribriform Carcinoma,Cribriform Carcinomas,Granular Cell Adenocarcinoma,Granular Cell Adenocarcinomas,Granular Cell Carcinoma,Granular Cell Carcinomas,Malignant Adenoma,Malignant Adenomas,Oxyphilic Adenocarcinoma,Oxyphilic Adenocarcinomas,Tubular Adenocarcinoma,Tubular Adenocarcinomas,Tubular Carcinoma,Tubular Carcinomas

Related Publications

I Campodónico, and A Soldati, and A Rodríguez

[Results of the treatment of ovarian cancer with Endoxan].

July 1962, Medizinische Klinik,

I Campodónico, and A Soldati, and A Rodríguez

[Surgery and endoxan therapy in ovarian carcinoma].

June 1971, Archiv fur Gynakologie,

I Campodónico, and A Soldati, and A Rodríguez

[Endoxan pretreatment in apparently inoperable ovarian carcinoma?].

March 1962, Geburtshilfe und Frauenheilkunde,

I Campodónico, and A Soldati, and A Rodríguez

Ovarian carcinoma treated with cyclophosphamide (Endoxan).

September 1968, Singapore medical journal,

I Campodónico, and A Soldati, and A Rodríguez

[Tissue reaction in ovarian carcinoma after cyclophosphamide (Endoxan) therapy].

January 1969, Pathologia et microbiologia,

I Campodónico, and A Soldati, and A Rodríguez

[Prolonged intraperitoneal chemotherapy of ovarian tumors with Endoxan].

January 1968, Gynaecologia. International monthly review of obstetrics and gynecology. Revue internationale mensuelle d'obstetrique et de gynecologie. Monatsschrift fur Geburtshilfe und Gynakologie,

I Campodónico, and A Soldati, and A Rodríguez

[Late recurrence of ovarian carcinoma treated with endoxan].

August 1976, Wiadomosci lekarskie (Warsaw, Poland : 1960),

I Campodónico, and A Soldati, and A Rodríguez

[Effect of endoxan on ovarian carcinomas in vitro. Cytochemical study].

January 1972, Archiv fur Gynakologie,

I Campodónico, and A Soldati, and A Rodríguez

[Report on the management of advanced ovarian cancer using Endoxan (Asta) and cyclophosphamide preparations].

July 1967, Zentralblatt fur Gynakologie,

I Campodónico, and A Soldati, and A Rodríguez

[Endoxan in palliative treatment of breast cancer].

May 1972, Wiadomosci lekarskie (Warsaw, Poland : 1960),